"Liver Cirrhosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Descriptor ID |
D008103
|
| MeSH Number(s) |
C06.552.630
|
| Concept/Terms |
Liver Cirrhosis- Liver Cirrhosis
- Cirrhosis, Liver
- Cirrhoses, Liver
- Liver Cirrhoses
- Hepatic Cirrhosis
- Cirrhoses, Hepatic
- Cirrhosis, Hepatic
- Hepatic Cirrhoses
|
Below are MeSH descriptors whose meaning is more general than "Liver Cirrhosis".
Below are MeSH descriptors whose meaning is more specific than "Liver Cirrhosis".
This graph shows the total number of publications written about "Liver Cirrhosis" by people in this website by year, and whether "Liver Cirrhosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 4 | 4 |
| 1998 | 2 | 1 | 3 |
| 1999 | 0 | 2 | 2 |
| 2000 | 2 | 1 | 3 |
| 2001 | 2 | 0 | 2 |
| 2002 | 2 | 3 | 5 |
| 2003 | 2 | 3 | 5 |
| 2004 | 0 | 2 | 2 |
| 2005 | 3 | 1 | 4 |
| 2006 | 4 | 1 | 5 |
| 2007 | 2 | 1 | 3 |
| 2008 | 6 | 0 | 6 |
| 2009 | 5 | 3 | 8 |
| 2010 | 3 | 1 | 4 |
| 2011 | 3 | 1 | 4 |
| 2012 | 4 | 2 | 6 |
| 2013 | 4 | 2 | 6 |
| 2014 | 6 | 2 | 8 |
| 2015 | 7 | 3 | 10 |
| 2016 | 14 | 4 | 18 |
| 2017 | 10 | 2 | 12 |
| 2018 | 5 | 3 | 8 |
| 2019 | 12 | 2 | 14 |
| 2020 | 3 | 8 | 11 |
| 2021 | 3 | 15 | 18 |
| 2022 | 0 | 9 | 9 |
| 2023 | 0 | 14 | 14 |
| 2024 | 3 | 4 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Liver Cirrhosis" by people in Profiles.
-
Semaglutide 2.4?mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Aliment Pharmacol Ther. 2024 Dec; 60(11-12):1525-1533.
-
Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma. JAMA. 2024 09 24; 332(12):1013-1014.
-
Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis. Clin Gastroenterol Hepatol. 2024 Dec; 22(12):2367-2377.
-
Cost burden of cirrhosis and liver disease progression in metabolic dysfunction-associated steatohepatitis: A US cohort study. J Manag Care Spec Pharm. 2024 Sep; 30(9):929-941.
-
Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi. Hepatology. 2024 08 01; 80(2):488-499.
-
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024 02 08; 390(6):497-509.
-
Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol Hepatol. 2024 Mar; 9(3):218-228.
-
Implementation of a liver health check in people with type 2 diabetes. Lancet Gastroenterol Hepatol. 2024 Jan; 9(1):83-91.
-
Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis. Diabetes Obes Metab. 2024 Jan; 26(1):191-200.
-
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. Hepatology. 2024 03 01; 79(3):674-689.